Unlocking more answers
EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information.
Evalution® runs fast immunoassay panels consisting of biomarkers of highly variable concentration
Evalution® is the first solution able to qualify [how strong, how fast] an immune response directly from a clinical sample, on top of the current practice of quantification [how much] and specification [how specific].”
MyCartis offers an open platform approach allowing partners to co-develop assays or port existing assay products on the platform. MyCartis also supports an OEM approach (DMAT® technology inside) in which case MyCartis’ technology is integrated in partner’s existing or new instruments.